FDA approves use of Bracco's MultiHance injection in MRA
08:52 EDT 30 Jul 2012 | Pharmaceutical Business Review
The Bracco Diagnostics has gained FDA approval for the use of MultiHance (gadobenate dimeglumine) injection, 529mg/ml, in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular d..
Original Article: FDA approves use of Bracco's MultiHance injection in MRA
More From BioPortfolio on "FDA approves use of Bracco's MultiHance injection in MRA"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
